ASNC2012 Abstract Submission Guidelines
Please review the guidelines below prior to submitting an abstract for ASNC2012.
Printer-Friendly Abstract Submission Guidelines (PDF)
- Original scientific abstracts must be submitted by 5:00 p.m. EST on April 10, 2012. ASNC is not responsible for abstracts submitted after the deadline.
- Late-breaking clinical trial abstracts must be submitted by 5:00 p.m. EST on June 15, 2012.
- Incomplete submissions will not be processed. Verify your information carefully before submitting. Your abstract will not be edited. Do not submit your abstract more than once. You may request a Confirmation of Receipt e-mail containing your unique abstract number. Please retain this number for your records.
- Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the meeting, if not justified, will jeopardize future acceptance of abstracts.
- There is a limit of four (4) abstracts an investigator may submit. If an abstract is selected, the presenter must be one of the co-authors listed. An investigator may present no more than two abstracts. If more than two abstracts are accepted from an investigator, one of the co-authors must present any additional abstracts.
- There is a 2,500-character limit for each abstract. Each table or graphic counts as 425 characters.
- Investigators should not submit the same research more than once. Abstracts that appear to be replicate versions of a single study will be rejected.
- Abstracts may not be eligible for consideration if the same work has been presented at a national or international meeting held in North America before ASNC2012.
- Abstracts are not eligible for consideration if the manuscript has been or will be published before ASNC2012.
- The submitter acts on behalf of all authors, and in submitting an abstract, transfers to the American Society of Nuclear Cardiology the copyright and all other rights in the material comprising the abstract if the abstract is accepted. Authors reserve the following: a) all proprietary rights other than the copyright, such as patent rights; and b) the right to use all or part of the abstract in future works of their own. The American Society of Nuclear Cardiology, as holder of the copyright on the accepted abstract, reserves all right to create derivative works in both print and digital formats.
- All abstracts are disclosed to members of the review selection committee as well as ASNC employees and contractors as necessary in connection with the Annual Scientific Session. Those abstracts that are accepted for presentation are published and are publicly available in advance of the meeting. Abstracts accepted for oral programming of late-breaking clinical trials will not be published. Abstracts not accepted for presentation are not published and remain confidential.
- Notwithstanding these policies and procedures, ASNC is not subject to any confidentiality requirements with respect to submitted abstracts. In addition, compliance with any disclosure or nondisclosure requirements that apply to researchers or research sponsors (whether under federal securities laws, contract agreement, or otherwise) is the sole responsibility of the researcher and/or sponsor, and not the American Society of Nuclear Cardiology.
